PENTIXAPHARM
6.2.2020 12:48:05 CET | Business Wire | Press release
PentixaPharm announced today to have secured € 15 million in a series A financing round led by ELSA Eckert Life Science Accelerator.
PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers. Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System (CNS) Lymphoma while supporting proof-of-concept studies in various other indications.
Interviews:
“With the renowned expertise of the PentixaPharm team, the company is well positioned to bring the lead-compounds PentixaFor and PentixaTher with an effective clinical development program to the next level. We are thrilled to accompany this venture.”,
says Phillip Eckert, Responsible Programme Manager and Partner at ELSA.
“Scintomics is very excited about this new partnership marking another important milestone towards a strong positioning of PentixaPharm as radiopharmaceutical development specialist” , comments Saskia Kropf, CEO of Scintomics. Prof. Hans-Jürgen Wester, founder of Scintomics, adds: “We are enthusiastic by this round A financing to advance the CXCR4 program. Preclinical and clinical data so far have demonstrated encouraging evidence and good potential for targeted cancer therapies. Now with the experienced development team of PentixaPharm, we are sure to quickly establish this theranostic approach towards meaningful clinical trials.”
“We are delighted that in ELSA we have found a strong financing partner with an outstanding expertise in the radiopharmaceutical field. The proceeds of the series A financing will enable us to bring a new treatment for CNS Lymphoma, up to today a disease with limited treatment options, a little closer to patients in need”, adds Anna Steeger, Co-founder of 1717 LSV GmbH and CEO of PentixaPharm.
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The [68 Ga]Gallium based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukemia, lymphoma, and multiple myeloma – but also for solid tumors like adrenocortical carcinoma and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke can be visualised with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About ELSA Eckert Life Science Accelerator
ELSA, a subsidiary of Eckert Wagniskapital und Frühphasenfinanzierung, is a Berlin-based life science incubator with over two decades of experience in the venture capital industry. ELSA invests primarily in start-up companies, which are in need of first-round venture capital financing and actively supports them during the transformation process from start-ups into mature companies.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalised cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005461/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Convatec’s Advanced Wound Care Innovation Leads the Industry at European Wound Management Association (EWMA) 20265.5.2026 16:11:00 CEST | Press release
Convatec will showcase new clinical and real‑world evidence across next‑generation foam technology, nitric oxide‑generating dressings, and Wound HygieneConvatec-sponsored scientific symposia to spotlight patient-centred innovation supported by robust in-vitro and clinical data enabling HCPs to deliver better outcomesConvatec to unveil Aquacel™ ConvaFiber™ in its European debut ahead of scale-up later this year Convatec, a leading medical products and technology company focused on chronic condition management, takes to the stage to showcase the breadth, depth and momentum behind its Advanced Wound Care innovation pipeline at the European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, from 6–8 May 2026. Convatec’s industry-leading Advanced Wound Care innovation is supported by compelling new data from randomised controlled trials (RCTs) and real-world studies, with 13 abstracts accepted for publication and presentation at EWMA evaluating outcomes in hard-to-heal
Laserfiche Recognized as a Leader in 2026 Gartner® Magic Quadrant™ for Document Management5.5.2026 16:00:00 CEST | Press release
Laserfiche named a Leader for the second consecutive time based on its Completeness of Vision and Ability to Execute Laserfiche — the leading SaaS provider of intelligent content management — has been positioned as a Leader in the 2026 Magic Quadrant for Document Management. Laserfiche believes this recognition underscores the company’s commitment to empowering organizations to transform complex, operational business processes through AI-powered content management. “It’s incredible to see Laserfiche recognized during the same week as our annual Empower conference, where we announced our latest agentic AI capabilities,” said Thomas Phelps, senior vice president of corporate strategy and chief information officer at Laserfiche. “We believe being positioned as a Leader — and receiving the highest overall rating among 16 vendors in Gartner Peer Insights, with a 4.7 out of 5.0 based on over 1,300 reviews as of April 30, 2026 — reflects our relentless focus on product innovation and deliveri
De’ Longhi and La Marzocco Redefine the Coffee Experience at Milan Design Week 20265.5.2026 15:43:00 CEST | Press release
In the heart of Brera, Milan’s most iconic neighbourhood, the Group celebrated coffee, design, and innovation with two immersive spaces: CASA La Marzocco and The Smallest Coffee Shop at Home with De’ Longhi Milan Design Week annually transforms the city into a global stage for design culture and functional aesthetics, attracting hundreds of thousands of visitors and creatives from around the world to define the year's leading trends. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505367702/en/ Once again, the De’ Longhi Group took the spotlight with activations dedicated to the evolving world of coffee, spanning at-home rituals and out-of-home professional settings. For Milan Design Week 2026, De’ Longhi presented 'The Smallest Coffee Shop at Home,' where the brand reimagined its bestselling machines in the style of cafes around the world. The idea was developed in collaboration with master miniaturist Simon Weisse. The v
Submission Deadline for 5th Cycle of the Mohammed bin Rashid Al Maktoum Global Water Award Extended to 30 September 20265.5.2026 15:41:00 CEST | Press release
In response to requests from a large number of participants, the UAE Water Aid Foundation (Suqia UAE) has extended the submission deadline for the fifth cycle of the Mohammed bin Rashid Al Maktoum Global Water Award to 30 September 2026. The extension aims to enable the widest possible participation from applicants around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505894901/en/ Submission deadline for 5th cycle of the Mohammed bin Rashid Al Maktoum Global Water Award extended to 30 September 2026 (Photo: AETOSWire) Launched by HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and overseen by Suqia UAE under the umbrella of the Mohammed bin Rashid Al Maktoum Global Initiatives, the award supports research and development efforts to develop sustainable solutions to address the global water crisis using renewable energy. It aims to tackle water scarcity
LTM and Uniphore Partner to Scale Domain-Specific AI Across Core Business Processes5.5.2026 15:15:00 CEST | Press release
Uniphore’s Business AI Cloud will power LTM’s BlueVerse™ ecosystem to deliver industry-specific small language models and AI agents for core enterprise workflows Uniphore, the Business AI Company, and LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic partnership focused on the joint development of industry- and domain-specific AI solutions that combine small language models (SLMs), AI agents, and deep domain expertise. As AI adoption matures, enterprises are shifting to smaller, purpose‑built models and agents for greater precision and control. The partnership brings this approach to core business processes with governance, security, and compliance by design. Uniphore’s Business AI Cloud will power LTM’s BlueVerse™ ecosystem and global delivery, unifying enterprise data, models, and AI agents on a secure, sovereign platform. LTM will drive industry expertise, client implementation, and AI‑led transformation, while Uniphore provides the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom